The potentiality of grape seed extract as a novel anti-hepatitis C virus agent

Journal of Medical Sciences (Faisalabad)

Volumn 12, Issue 4, 2012, Pages 107-113

  Sharaf, Mona ^a   El Deeb, Nehal M ^a   El Adawi, Hala I ^a  

^a Universities and Research Institutes District   (Egypt)

Author keywords

Antioxidant; Cytotoxicity; Epicatechin; HepG2; PCR

Indexed keywords

CATECHIN; EPICATECHIN; GALLIC ACID; GRAPE SEED EXTRACT; HEPATITIS C VACCINE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; GENE AMPLIFICATION; GRAPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 84871907560     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2012.107.113     Document Type: Article

References (31)

1. Abd El Mohsen, M.M., G. Kuhnle, A.R. Rechner, H. Schroeter, S. Rose, P. Jemer and C. A. Rice-Evans, 2002. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radie. Biol. Med., 33: 1693-1702.
2. Abd El-Wahab, A and H. El-Adawi, 2009. Grape seed and milk thistle extracts as promising anti-viral agents against hepatitis C virus. Proceedings of the 1st Euro-Med Conference on Plant Natural Products from Biodiversity to Bioindustry, December 8-10, 2009, Cairo-Egypt.
3. Abd El-Wahab, A., H. El-Adawi and H. Kassem, 2008. Towards understanding the hepatoprotective effect of grape seed extracts on cholesterol-fed rats. Aust. J. Basic Applied Sci., 2: 412-417.
4. Alter, M.J., 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol., 13: 2436-2441.
5. Asselah, T., E. Estrabaud, I. Bieche, M. Lapalus and S. De Muynck et al., 2010. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int., 30: 1259-1269.
6. Borenfreund, E. and J.A. Puemer, 1985. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett., 24: 119-124.
7. Calland, N., A. Albecka, S. Belouzard, C. Wychowski and G. Duverlie et al, 2012. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology., 55: 720-729.
8. Chang, W.T., Z.H. Shao, T.L.V. Hoek, E. McEntee and S.R. Mehendale et al., 2006. Cardioprotective effects of grape-seed proanthocyanidin, baicalin and wogonin: Comparison between acute and chronic treatment. Am. J. Chin. Med., 34: 363-365.
9. Ciesek, S., T. von Hahn, C.C. Colpitts, L.M. Schang and M. Friesland et al., 2011. The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entry. Hepatology., 54: 1947-1955.
10. Criswell, K.A., G. Krishna, D. Zielinski, G.C. Urda, J.C. Theiss, P. Juneau and M.R. Bleavins, 1998. Use of acridin orange in: Flow cytomertric assessment of micronuclei induction. Mutat. Res., 414: 63-75.
11. El-Adawi, H., M. Abdel Mohsen, D. Youssef and S. El-Sewedy, 2006. Study on the effect of grape seed extract on hypercholestrolemia: Prevention and treatment. Int. J. Pharmacol., 2: 593-600.
12. El-Adawi, H., M. El-Demellawy and A. Abd El-Wahab, 2011 a. Some medicinal plant extracts exhibit potency against viral hepatitis C. J. Biosci. Tech., 2: 223-231
13. El-Adawi, H., D. El-Azhary, A. Abd El-Wahab, M. El-Shafeey and M. Abdel-Mohsen, 2011b. Protective effect of milk thistle and grape seed extracts on fumonisin B1 induced hepato-and nephro-toxicity in rats. J. Med. Plants Res., 5: 6316-6327.
14. Hafer, K., K.S. Iwamoto and R.H. Schiestl, 2008. Refinement of the dichlorofluorescein assay for flow cytometric measurement of reactive oxygen species in irradiated and bystander cell populations. Radit. Res., 169: 460-468.
15. Jawaid, A. and A.K. Khuwaja, 2008. Treatment and vaccination for hepatitis C: Present and future. J. AyubMed. Coll. Abbottabad, 20: 129-133.
16. Kato, N., M. Ikeda, T. Mizutani, K. Sugiyama, M. Noguchi, S. Hirohashi and K. Shimotohno, 1996. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn. J. Cancer Res., 87: 787-792.
17. Koike, K., 2005. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: Lessons from animal model studies. Clin. Gastroenterol. Hepatol., 3: S132-S135.
18. Komurian-Pradel, F., G. Paranhos-Baccala, M. Sodoyer, P. Chevallier, B. Mandrand, V. Lotteau and P. Andre, 2001. Quantitation of HCV RNA using real-time PCR and fluorimetry. J. Virol. Methods, 95: 111-119.
19. Lehman, E.M. and M.L. Wilson, 2009. Epidemic hepatitis C virus infection in Egypt: Estimates of past incidence and future morbidity and mortality. J. Viral Hepat., 16: 650-658.
20. Lohr, H.F., B. Goergen, K.H. Meyer zum Buschenfelde and G. Gerken, 1995. HCV replication inmononuclear cells stimulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alpha. J. Med. Virol., 46: 314-320.
21. Maurya, P.K. and S. Prakash, 2011. Intracellular uptake of (-)epicatechin by human erythrocytes as a function of human age. Phytother. Res., 25: 944-946.
22. Munir, S., S. Saleem, M. Idrees, A. Tariq and S. Butt et al., 2010. Hepatitis C Treatment: Current and future perspectives. Virol. J., Vol. 7.
23. Okuda, M., K. Li, M.R. Beard, L.A. Showalter, F. Scholle, S.M. Lemon and S. A. Weinman, 2002. Mitochondrial injury, oxidative stress and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology, 122: 366-375.
24. Ray, S.D., H. Parikh, E. Hickey, M. Bag chi and D. Bagchi, 2001. Differential effects of IH636 grape seed proanthocyanidin extract and a DNA repair modulator 4- aminobenzamide on liver microsomal cytochrome 4502E1-dependent aniline hydroxylation. Mol. Cell Biochem., 218: 27-33.
25. Reichard, O., G. Norkrans, A. Fiyden, J.H. Braconier, A. Sonnerborg and O. Weiland, 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet, 351: 83-87.
26. Schroeter, H., C. Heiss, J. Balzer, P. Kleinbongard and C.L. Keen et al., 2006. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA., 103: 1024-1029.
27. Schvarcz, R., Z.B. Yun, A. Sonnerborg and O. Weiland, 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol., 46: 43-47.
28. WHO, 2009. Sixty second world health assembly. World Health Organization, Viral Hepatitis Report, A.62/22, pp: 1-5.
29. Wang, C.Z., A. Fishbein, H.H. Aung, S.R. Mehendale and W.T. Chang et al., 2005. Polyphenol contents in grape-seed extracts correlate with antipica effects in cisplatin-treated rats. J. Alter. Complement Med., 11: 1059-1065.
30. Waris, G., J. Turkson, T. Hassanein and A. Siddiqui, 2005. Hepatitis C virus (HCV) constitutively activates stat-3 via oxidative stress: role of stat-3 in HCV replication. J. Virol., 79: 1569-1580.
31. Zuo, G., Z. Li, L. Chen and X. Xu, 2007. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral. Res., 76: 86-92.